glp 1 hashimoto's GLP-1 Genetics: How Genes Affect Appetite, Semaglutide, and Tirzepatide Response GLP-1 with Hashimoto's Disease: Safety

Abstract The paradigm of one drug against multiple targets, known as unimolecular polypharmacology, offers the potential to improve efficacy while overcoming some adverse events associated with the treatment

While not everyone will experience anxiety on GLP-1s, the potential is real and worth understanding

A phase 2 study (MARIPOSA randomized trial) demonstrated that, in patients with OSA, administration of aroxybutynin (an antimuscarinic agent) combined with atomoxetine (a norepinephrine reuptake inhibitor) led to modest but significant reductions in AHI (AHI reduction of 5.9 events/hour greater than placebo) over a 4-week period, though the use of atomoxetine was also associated with a reduction of total sleep time by approximately 21 min

NG28 Type 2 diabetes in adults: visual summary choosing medicines for first-line and further treatment

Diabetes medications: GLP-1s can increase hypoglycemia risk when combined with insulin or sulfonylureas